Lead Sponsor

University Hospital, Martin

Collaborators

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•Age ≥ 18 years
•Primary kidney transplantation (living or dead donor)
•Stable kidney transplant recipients (≥ 6 months post-transplantation)
•Stable graft function defined as eGFR ≥ 30 mL/min/1.73 m² with no significant change (\>15%) in the last 3 months
•No episodes of acute rejection within the last 6 months
•On stable immunosuppressive therapy for at least 3 months
•Ability to provide written informed consent
•Willingness and ability to provide stool, urine, and blood samples at specified time points

•Use of antibiotics, probiotics, or prebiotics within 4 weeks prior to enrollment
•Active gastrointestinal disease (e.g., Crohn's disease, ulcerative colitis, celiac disease)
•Severe intestinal motility disorders or chronic diarrhea
•Advanced liver disease (Child-Pugh C)
•Active infection or systemic inflammatory disease requiring treatment
•Uncontrolled diabetes mellitus (HbA1c \> 9%)
•Known allergy or intolerance to SCFA or ingredients in the supplement
•Participation in another interventional clinical trial within the past 30 days
•Pregnancy or breastfeeding
•Hospitalization within 30 days prior to enrollment
•Any condition which, in the opinion of the investigator, may compromise the safety of the participant or the integrity of the study data

Related studies

NCT06535568 · Coronary Disease, Heart Diseases, and more

NCT07006831 · Kidney Disease, Kidney Transplant, and more

NCT04334135 · Racial Disparities, Blood Pressure, and more

NCT06398977 · Peritoneal Dialysis Complication, Renal Function Aggravated, and more

NCT07497958 · Renal Cell Carcinoma (RCC), Renal Function Abnormal

Impact of SCFA Supplementation on Gut Microbiome Composition of Kidney Transplant Recipients